Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
J.L. Pérez-García (1,9), C. Prior (2,9), F. Guillén-Grimá (3), V. Segura (4), A. González (5), A. Panizo (6), I. Melero (7), E. Grande-Pulido (8), A. Gúrpide (1), I. Gil-Bazo (1) and A. Calvo (2)
(1) Department of Medical Oncology, University Clinic of Navarra, University of Navarra, Pamplona, Spain.
(2) Division of Oncology, CIMA, University of Navarra, Pamplona, Spain.
(3) Department of Preventive Medicine, University Clinic of Navarra, University of Navarra, Pamplona, Spain.
(4) Genomics, Proteomics and Bioinformatics Unit, CIMA. University of Navarra, Pamplona, Spain.
(5) Department of Biochemistry, University Clinic of Navarra, University of Navarra, Pamplona, Spain.
(6)Department of Pathology, University Clinic of Navarra, University of Navarra, Pamplona, Spain.
(7) Department of Internal Medicine, University Clinic of Navarra and CIMA, University of Navarra, Pamplona, Spain.
(8) Department of Medical Oncology, Pfizer Inc., Madrid, Spain
Revista: British Journal of Cancer
Fecha: 01/12/2009Medicina Preventiva Bioquímica Clínica Oncología Médica
Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predictive markers to identify the most adequate treatment for each patient are needed. Our objective was to identify potential predictive markers of sunitinib activity in MRCC.
We collected sequential serum samples from 31 patients treated with sunitinib. Sera of six patients with extreme phenotypes of either marked responses or clear progressions were analysed with a Human Cytokine Array which evaluates 174 cytokines before and after treatment. Variations in cytokine signal intensity were compared between both groups and the most relevant cytokines were assessed by ELISA in all the patients.
Twenty-seven of the 174 cytokines varied significantly between both groups. Five of them (TNF-alpha, MMP-9, ICAM-1, BDNF and SDF-1) were assessed by ELISA in 21 evaluable patients. TNF-alpha and MMP-9 baseline levels were significantly increased in non-responders and significantly associated with reduced overall survival and time-to-progression, respectively. The area under the ROC curves for TNF-alpha and MMP-9 as predictive markers of sunitinib activity were 0.83 and 0.77.
Baseline levels of TNF-alpha and MMP-9 warrant further study as predictive markers of sunitinib activity in MRCC. Selection of patients with extreme phenotypes seems a valid method to identify potential predictive factors of response.
CITA DEL ARTÍCULO Br J Cancer. 2009 Dec 1;101(11):1876-83
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.